Real Luck Group Ltd. — Management Reports 2020

Apr 23, 2020

ELEPHANT HILL CAPITAL INC. (also referred to as "Elephant Hill" or the "Corporation")

MANAGEMENT'S DISCUSSION & ANALYSIS FOR THE YEAR ENDED DECEMBER 31, 2019

The following discussion and analysis should be read in conjunction with the financial statements for the period ended December 31, 2019 prepared in accordance with International Financial Reporting Standards ("IFRS"). Additional information regarding the Corporation is available on SEDAR at www.sedar.com.

All dollar figures included therein and in the following discussion analysis are quoted in Canadian dollars unless otherwise noted.

DATE

This management's discussion and analysis ("MD&A") is dated March 20, 2020 and relates to the year ended December 31, 2019. The discussion in this management's discussion and analysis focuses on this period. Estimates and forward-looking information are based on assumptions of future events and actual results may vary from these estimates.

DESCRIPTION OF ELEPHANT HILL'S BUSINESS AND OVERALL PERFORMANCE

Elephant Hill was incorporated pursuant to the provisions of the Business Corporations Act (Alberta) on January 15, 2018. The Company is a Capital Pool Company ("CPC") as defined pursuant to Policy 2.4 of The TSX Venture Exchange (the "TSXV") and is seeking to identify and evaluate corporations, businesses or assets for acquisition and once identified and evaluated, to negotiate an acquisition or participation subject to receipt of shareholder and regulatory approval.

The Company issued seed stock of 2,000,000 common shares at a price of $0.05 on January 15, 2018 to founders of the Company.

On June 15, 2018, the Company announced the completion of its initial public offering (the "IPO") of 5,000,000 common shares at the price of $0.10 per common share and filed for listing as a Capital Pool Company on the TSX Venture Exchange. The common shares of the Company commenced trading on June 20, 2018 under the trading symbol EH.P.

RISKS AND UNCERTAINTIES

The Corporation does not have a history of earnings, nor has it paid any dividends. The Corporation has only limited funds and there is no assurance that the Corporation will identify a business or asset that warrants acquisition or participation within the time limitations permissible under the policies of the TSXV, at which time the exchange may suspend or de-list the Corporation's shares from trading.

SELECTED FINANCIAL INFORMATION

The Corporation was incorporated on January 15, 2018 and was not yet a "Reporting Issuer" pursuant to applicable securities legislation until April 23, 2018 the date of the final receipt for the Prospectus as issued by the Alberta, British Columbia and Saskatchewan Securities Commissions, thereby becoming a "Reporting Issuer" in each of the provinces of Alberta, British Columbia and Saskatchewan.

The following table is a summary of selected financial information (in Canadian dollars) derived from the Corporation's interim financial statements prepared in accordance with IFRS:

	December 31, 2019
Total assets	$381,313
Total liabilities	15,832
Net loss and comprehensive loss for the period	(51,107)
Basic and diluted net loss per share for the period	$(0.01)
Weighted average number of common shares outstanding	7,000,000

The financial information follows:

For the year ended December 31, 2019 the Corporation reported no discontinued operations and declared no cash dividends.

RESULTS OF OPERATIONS

During the year ending December 31, 2019, the Company incurred a loss of $51,107 which consisted of $24,451 in professional fees, $16,754 in travel expenses, $12,944 in ongoing general and administration costs, and was partially offset by $3,042 in interest income.

During the period from Incorporation on January 15 to December 31, 2018, the Corporation incurred a loss of $130,983 which consisted of $54,922 in share-based payments, $31,242 in professional fees, $22,195 in ongoing general and administration costs, and $17,624 in travel expenses.

OUTSTANDING SHARE DATA

Common Shares

As at March 20, 2020, the Corporation had 7,000,000 common shares issued and outstanding.

Stock Options

As at March 20, 2020, there were 1,200,000 stock options outstanding entitling the holders thereof the right to purchase one common share for each option held as follows:

Numbers of options
outstanding	Exercise price		Expiry Date
500,000	$	0.10	June 15, 2020
700,000	$	0.10	June 15, 2023
1,200,000

LIQUIDITY AND CAPITAL RESOURCES

As at December 31, 2019, the Corporation had working capital of $365,481 comprised of cash and other receivables which management considers to be sufficient for the Corporation to meet its ongoing obligations.

CHANGE IN ACCOUNTING POLICIES

Initial adoption of new accounting standards

Adoption of new accounting standards have been disclosed in Note 4 of the Company's condensed consolidated interim financial statements for the year ended December 31, 2019 and period from incorporation on January 15 to December 31, 2018.

OFF-BALANCE SHEET ARRANGEMENTS

The Corporation has no off-balance sheet arrangements.

TRANSACTIONS WITH RELATED PARTY

The Company has identified its directors and certain officers as its key management personnel. Current directors and officers of the Company are as follows:

Mohammad Fazil, President, CEO, CFO, and Director Eamon Hurley, Director and Secretary Sarshar Ahmad, Director Jonathan Gilbert, Director

Key management personnel compensation

All related party transactions are carried out in the normal course of operation and are recorded at fair value. There was no key management compensation or other related party transactions during the year ended December 31, 2019.

Related party balances

As at December 31, 2019, there were $nil (December 31, 2018, $nil) payable to related parties.

FINANCIAL INSTRUMENTS

The Company's senior management oversees the management of these risks and advises on financial risks and the appropriate financial risk governance framework for the Company. The Company's senior management provides assurance that the Company's financial risk-taking activities are governed by appropriate policies and procedures and that financial risks are identified, measured, and managed in accordance with the Company's policies and group risk appetite. All derivative activities, if any, for risk management purposes are carried out by a team that has the appropriate skills, experience, and supervision. It is the Company's policy that no trading in derivatives for speculative purposes shall be undertaken.

The Board of Directors reviews and agrees policies for managing each of these risks which are summarized below:

Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Corporation's financial assets consist of cash and cash equivalents and other receivables. The Company's maximum exposure to credit risk, as at period-end, is the carrying value of its financial asset. The company mitigates credit risk by holding financial instruments within financial institutions of high creditworthiness.

Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities. The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at December 31, 2019, the Company had cash and cash equivalents of $378,271

Other risks

None of the Company's future cash flows of financial instruments are subject to change from other price changes and currency risks.

CRITICAL ACCOUNTING ESTIMATES

This MD&A is based on the financial statements which have been prepared in accordance with IFRS. The preparation of the financial statements requires that certain estimates and judgments are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances.

The accounting estimates for share based payments is based on the Black-Scholes option valuation model which was developed for use in estimating the fair value of traded options which were fully tradable with no vesting restrictions. This option valuation model requires the input of highly subjective assumptions including the expected stock price volatility. Since the Corporation's stock options have characteristics significantly different from those of traded options and since changes in the subjective input assumptions can materially affect the calculated fair value, such value is subject to measurement uncertainty.

CAPITAL RISK MANAGEMENT

The Corporation's capital currently consists of common shares and options. The Corporation defines capital as total equity which was $365,481 at December 31, 2019. Its principal source of cash is from the issuance of common shares. The Corporation's capital management objectives are to safeguard its ability to continue as a going-concern and to have sufficient capital to be able to identify, evaluate and then acquire an interest in a business or assets.

The Corporation manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Corporation may attempt to issue new shares.

The proceeds raised from the issuance of common shares may only be used to complete the IPO and subsequent to the IPO, identify and evaluate assets or business for future investment, with the exception that not more than the lessor of 30% of the gross proceeds from the issuance of shares issued in the IPO may be used to cover prescribed costs of issuing the common shares or administrative and general expenses of the Corporation. These restrictions apply until the completion of a Qualifying Transaction.

SUBSEQUENT EVENTS

None.

PROPOSED TRANSACTIONS

On January 8, 2020 the Company signed a non-binding letter of intent to complete its Qualifying Transaction by acquiring all the issued and outstanding shares of Artos Pharma Inc. ("Artos") and Tassili Life Sciences Corp. ("Tassili"). Conditional to completion of required due-diligence, and required approvals of respective boards of directors, shareholders and regulatory authorities the Proposed Transaction will result in each shareholder of Artos and Tassili receiving one Elephant Hill common share for each Artos or Tassili share outstanding, and one Elephant Hill warrant or stock option for each warrant or stock option outstanding at the respective companies on the same terms.

In connection with the proposed transaction there will be issuance of between 33,750,000 and 42,500,000 Elephant Hill shares at $0.20 per share to existing shareholders of Artos and Tassili. Additionally proposed financing proceeds of between $4,000,000 and $7,000,000 will be raised through completion of a private placement of subscription receipts.

Following completion of the proposed transaction, Elephant Hill intends to list as a Tier 2 Life Sciences Issuer on the Exchange and continue with the business of each of Artos and Tassili, in the clinal stage treatment of advanced sarcomas and pre-clinical research of the applications of psilocybin and cannabidiol on neurological disorders, respectively.

The LOI establishes that the parties will enter into a definitive agreement with substantially the terms described in the Letter of Intent (and other terms and conditions customary for a transaction of this nature) on or before February 28th, 2020. As of the date of this MDA, the parties have not entered into a definitive agreement.

Summary of Quarterly Results

The following table provides selected quarterly unaudited financial data for the eight completed interim quarters since incorporation:

	Three months ended					January
	December31, 2019	September30, 2019	June 30,2019	March31, 2019	December31, 2018	September30, 2018	June 30,2018	15 toMarch31, 2018
Other
income	1,191	1,191	660	-	-	-	-	-
Net loss for
the period	(19,845)	(3,878)	(8,626)	(18,758)	(39,915)	(29,599)	(52,351)	(9,118)
Basic anddiluted loss
per share	(0.00)	(0.00)	(0.00)	(0.00)	(0.01)	(0.01)	(0.01)	(0.00)

Net loss increased for the three months ended December 31, 2019, primarily due to an increase in travel expenses incurred during management's search for suitable companies for the Company's qualifying transaction and expenses relating to the year-end audit.

Net loss decreased for the three months ended September 30, 2019, primarily due to a decrease in travel and general and administrative expenses, offset by increased return on interest from the company's GIC

Net loss decreased for the three months ended June 30, 2019, primarily due to an overall decrease in operating expenses as this was the first period since the Company terminated its letter of intent with Adcore that was to be the Company's Qualifying Transaction.

Net loss decreased for the three months ended March 31, 2019, primarily due to an overall decrease in operating expenses as this is the first period since the Company terminated its letter of intent with Adcore that was to be the Company's Qualifying Transaction.

Net loss increased for the three months ended December 31, 2018, primarily due to an overall increase in operating expenses related to significant travel and related operating expenses related to activity surrounding the intent to execute the Company's qualifying transaction with Adcore.

Net loss decreased for the three months ended September 30, 2018, primarily due to a decrease in sharebased compensation, which was a significant non-recurring expense during the previous quarter. This decrease was partially offset by an increase in travel expenses.

Net loss increased for the three months ended June 30, 2018, primarily due to an increase in share-based compensation.

Expenses for the period from incorporation on January 15 to March 31, 2018 related to general and administrative costs and professional fees.

FORWARD LOOKING INFORMATION

This MD&A contains forward-looking information in the "Risks and Uncertainties" and "Outlook" sections that involves material assumptions and known and unknown risks and uncertainties, certain of which are beyond the Corporation's control. Such assumptions, risks and uncertainties include, without limitation, those associated with, loss of markets, volatility of commodity prices, currency fluctuations, delays resulting from the inability to obtain required regulatory approvals and ability to access sufficient capital from internal and external sources, the effect of general economic conditions in Canada and the United States, industry conditions, changes in laws and regulations and changes in how they are interpreted and enforced, increased competition, the lack of qualified personnel or management, fluctuations in foreign exchange or interest rates, stock market volatility and market valuations of companies with respect to announced transactions and the final valuations thereof, and obtaining required approvals of regulatory authorities. The Corporation's actual results, performance or achievements could differ materially from those expressed in, or implied by, this forward-looking information and, accordingly, no assurances can be given that any of the events anticipated by the forward-looking information will transpire or occur, or if any of them do so, what benefits the Corporation will derive therefrom. The forward-looking information is made as at the date of this MD&A and the Corporation does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws.